All
Triplet Combination Data Add Evidence to Clinical Activity in aRCC
June 16th 2022Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16th 2022In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Post hoc Analysis of CLEAR Trial Shows Comparable OS Regardless of Subsequent Therapy in aRCC
June 15th 2022Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.
Dostarlimab Achieves High Complete Response Rate in Patients with dMMR Rectal Cancer
June 14th 2022Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
New Agent Investigated for Patients With RET Fusions Given a Prior RET Inhibitor
June 14th 2022In an interview with Targeted Oncology, Nathan Pennell, MD, PhD, discussed the basis of the LOXO-NGR-21001 trial evaluating LOXO-260 in patients who have previously received a prior selective RET inhibitor.
Improved PFS With Toripalimab Plus Chemotherapy in NSCLC Regardless of PD-L1 Status
June 13th 2022Combination of toripalimab and chemotherapy in the frontline setting shows survival benefit in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.
European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma
June 12th 2022The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Benefit of Asciminib Transforms Standard of Care for Patients With CML in Chronic Phase
June 10th 2022At the 2022 American Society for Clinical Oncology Annual Meeting, durable responses continued to be shown with asciminib compared with bosutinib in adult patients with chronic myeloid leukemia in chronic phase.
Tucatinib Added to First-Line Maintenance Under Investigation in HER2+ Metastatic Breast Cancer
June 9th 2022The addition of tucatinib to standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer will be examined in the ongoing phase 3 HER2CLIMB-05 trial.